Bank of New York Mellon’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Bank of New York Mellon’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,528	Closed	-$11K	–	4413
2016 Q2	$11K	Sell	25,528 -4,889	-16%	-$7.85K	﹤0.01%	4290
2016 Q1	$82K	Buy	30,417 +14,229	+88%	+$39.9K	﹤0.01%	4002
2015 Q4	$50K	Sell	16,188 -128	-0.8%	-$577	﹤0.01%	4190
2015 Q3	$73K	Sell	16,316 -1,344	-8%	-$7.89K	﹤0.01%	4189
2015 Q2	$101K	Buy	17,660 +1,293	+8%	+$8.82K	﹤0.01%	4047
2015 Q1	$146K	Buy	+16,367	New	+$131K	﹤0.01%	3974

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Bank of New York Mellon's EPRS Position: Q3 2016 in Review

Bank of New York Mellon sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 25,528 shares — an estimated $11K sold.

Bank of New York Mellon first reported a position in EPRS in Q1 2015 and held it in 6 quarters. The position peaked at $146K in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

Bank of New York Mellon reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
Bank of New York Mellon sold 25,528 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016, an estimated $11K.
Bank of New York Mellon first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 6 quarters.
Bank of New York Mellon's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $146K in Q1 2015.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Bank of New York Mellon's 13F filing for Q3 2016, filed 3 Nov 2016.